Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus rhamnosus R0011
- Development stage
- Unknown
- Lead developer
- Lallemand Health Solutions
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus rhamnosus R0011 (also known as Lacticaseibacillus rhamnosus R0011 or Rosell-11) is a probiotic bacterial strain that functions as a live biotherapeutic agent. Originally isolated in 1976 at Institut Rosell and currently part of the Lallemand Health Solutions portfolio, this strain is widely utilized for its ability to maintain intestinal homeostasis. Its mechanism of action involves competitive inhibition of pathogen adhesion, enhancement of the intestinal epithelial barrier, and immunomodulation through the downregulation of pro-inflammatory cytokines such as IL-1β, IL-8, and TNF-α. While frequently formulated in combination with Lactobacillus helveticus R0052 (under the brand name Lacidofil), R0011 has been independently investigated for its efficacy in treating antibiotic-associated diarrhea, as an adjuvant in Helicobacter pylori eradication, and for its potential benefits in alcoholic liver disease and the gut-brain axis.
- Brand names
- Lacidofil
- Other names
- Lacticaseibacillus rhamnosus R0011L. rhamnosus R0011
02
Targets
CD4 (T lymphocyte surface antigen)
Beyond the preview
Go deeper on Lactobacillus rhamnosus R0011.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus rhamnosus R0011.